Skip to main content
Medy-Tox Inc. logo

Medy-Tox Inc. — Investor Relations & Filings

Ticker · 086900 ISIN · KR7086900008 KO Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 086900

About Medy-Tox Inc.

https://www.medytox.com/?site_id=en

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서” (Quarterly Report) covering the period from January 1, 2026 to March 31, 2026 (1st quarter of the 27th fiscal year). It contains a full set of financial statements, notes, management’s analysis, audit opinion, and detailed tables. This matches the definition of an Interim / Quarterly Report (IR), not merely an announcement or summary. Therefore, it should be classified as IR. Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 92% confidence The document presents consolidated preliminary (잠정) operating results for Q1 2026, with key financial metrics (revenue, operating profit, net income) disclosed in table format as a fair public disclosure (‘공정공시’) rather than full audited financial statements. This aligns with an initial quarterly earnings announcement summarizing key results, matching the Earnings Release (ER) category. Q1 2026
2026-05-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 94% confidence The document is a statutory “Report on Large Holdings of Shares” (주식등의 대량보유상황보고서) filed by a major shareholder under the Korean Capital Markets Act. It details the number of shares, holding percentages, associated parties, and changes in ownership. This clearly matches the “Major Shareholding Notification” category (MRQ).
2026-04-28 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 85% confidence The document is a voluntary regulatory disclosure (“자율공시”) of Medytox’s corporate value enhancement plan, centered on future dividend policy and procedures. It is not an earnings release, dividend payment notice (DIV), capital raising announcement, or part of a formal annual/interim report. It does not announce an actual dividend amount and payment date, nor is it a share issuance or buyback. It is a standalone plan disclosure that doesn’t fit the other specific categories, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is an insider holdings report filed by an executive (“임원ㆍ주요주주 특정증권등 소유상황보고서”) detailing the director’s and major shareholder’s share ownership and transaction history (dates, quantities, prices). This matches the definition of a Director’s Dealing (insider share transactions by directors/executives).
2026-04-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 91% confidence The document is a regulatory filing titled “주식등의 대량보유상황보고서(일반)” (Report on Major Shareholding Situation), detailing changes in shareholdings by the reporting person and related parties under Korean capital markets law. This matches the “Major Shareholding Notification” category (Code MRQ).
2026-04-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.